Breaking News

EU Targets Bortnikov, Head of Russian Secret Service, in Draft of Sanctions
Tweet TWEET

Chelsea Therapeutics to Present at the 25th Annual ROTH Conference

Chelsea Therapeutics to Present at the 25th Annual ROTH Conference

CHARLOTTE, N.C., March 12, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics
International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 25^TH Annual
ROTH Conference at 3:30 PM PT on Tuesday, March 19, 2013 in Dana Point, CA.

Joseph G. Oliveto, Chelsea's Interim Chief Executive Officer will provide a
corporate update and an overview of the Northera™ (droxidopa) development
program.

Mr. Oliveto's presentation will be webcast live and archived for 30 days on
Chelsea's website, www.chelseatherapeutics.com.

About Chelsea Therapeutics

Chelsea Therapeutics (Nasdaq:CHTP) is a biopharmaceutical development company
that acquires and develops innovative products for the treatment of a variety
of human diseases, including central nervous system disorders. Chelsea is
currently pursuing FDA approval in the U.S. for Northera™ (droxidopa), a
novel, late-stage, orally-active therapeutic agent for the treatment of
symptomatic neurogenic orthostatic hypotension in patients with primary
autonomic failure. For more information about the Company, visit
www.chelseatherapeutics.com

CONTACT: Investors:
         Fara Berkowitz/Susan Kim
         Argot Partners
         212-600-1902
         fara@argotpartners.com
         susan@argotpartners.com
        
         Media:
         David Pitts
         Argot Partners
         212-600-1902
         david@argotpartners.com

Chelsea Therapeutics Logo